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Background: Patients undergoing repeat heart valve operations are a diverse popu-
lation. We assessed risk factors for operative mortality in patients undergoing a first
heart valve reoperation.
Methods: A retrospective review of hospital records was performed for 671 patients
who underwent first repeat heart valve operations between 1969 and 1998.
Univariable and multivariable analyses were performed.
Results: Operative mortality was 8.6%. Mortality fell each decade to 4.8% in the
most recent period (adjusted χ2 for linear trend P < .0005). Mortality increased
from 3.0% for reoperation for a failed repair or reoperation at a new valve site to
10.6% for prosthetic valve dysfunction or periprosthetic leak and to 29.4% for
endocarditis or valve thrombosis. Concomitant coronary artery bypass grafting was
associated with a mortality of 15.4% compared with 8.2% when it was not required.
Mortality for aortic valve replacement was 6.4%, mitral valve replacement 7.4%,
aortic and mitral valve replacement 11.5%, tricuspid valve replacement 25.6%,
periprosthetic leak repair 9.1%, and isolated valve repair 2.2%. Among 336 patients
requiring replacement of prosthetic valves, mortality was 26.1% for replacement of
a mechanical valve compared with 8.6% for replacement of a tissue valve (P <
.0005). Multivariable analyses identified year of reoperation, age, coronary artery
bypass grafting, indication, and replacement of a mechanical valve rather than a tis-
sue valve as significant explanatory variables for operative mortality.
Conclusions: Heart valve reoperations can be performed with an acceptable opera-
tive mortality. However, we have identified several categories of patients in whom
reoperation carries an increased risk.
The operative mortality associated with repeat heart valve surgery ishigher than for the initial valve operation.1 However, patients requir-ing heart valve reoperation are diverse in terms of both the initialoperation and the reoperation. We reviewed our total experience at asingle institution, from 1969 until 1998, of all patients undergoing afirst repeat heart valve operation to identify possible risk factors for
operative mortality.
From the Departments of Cardiac Surgerya
and Epidemiology and Public Healthb
(Queen’s University), Royal Victoria
Hospital, Belfast, Northern Ireland.
Received for publication Nov 13, 2000; revi-
sions requested Feb 8, 2001; revisions
received March 20, 2001; accepted for pub-
lication March 28, 2001.
Address for reprints: Mr H. O’Kane,
Department of Cardiac Surgery, Royal
Victoria Hospital, Belfast BT12 6BA,
Northern Ireland (E-mail: jmj12@hot-
mail.com).
J Thorac Cardiovasc Surg 2001;122:913-8
Copyright © 2001 by The American
Association for Thoracic Surgery
0022-5223/2001 $35.00 + 0 12/1/116470
doi:10.1067/mtc.2001.116470
Repeat heart valve surgery: Risk factors for operative
mortality
J. Mark Jones, MA, AFRCSa
Hugh O’Kane, MCh, FRCSa
Dennis J. Gladstone, FRCSa
Mazin A. I. Sarsam, FRCS(CTh)a
Gianfranco Campalani, MDa
Simon W. MacGowan, MCh, FRCSI(CTh)a
Jack Cleland, FRCSa
Gordon W. Cran, PhD, CStatb
TX
ET
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 5   913
Surgery for
Acquired
Cardiovascular
Disease
ED
ITO
RIA
L
CH
D
G
TS
A
CD
ET
CSP
TX
Patients and Methods
Between June 1968 and December 1998, a total of 5720 valve
operations (1083 valve repairs, 1195 tissue valve replacements,
and 3442 mechanical valve replacements) were performed at the
Royal Victoria Hospital. During this period, 671 patients had a first
reoperation (11.7% of all valve operations) for a subsequent valve
problem, although the first of these reoperations did not occur until
1969. Patients with congenital valve disorders who were 15 years
or younger at reoperation were excluded. Hospital records were
retrospectively reviewed and a computer database was constructed.
The pathologic state of the valve was obtained from operative and
pathologic reports. A 5-group classification of indication for reop-
eration was used, based on an original 4-group classification by
Lytle and associates2:
1. Failed repair/new native valve disease: All patients who had
a failed previous valve repair and patients who at reopera-
tion required repair or replacement of a valve different from
that operated on during the initial procedure.
2. Prosthetic valve dysfunction: Valve dysfunction resulting
from tissue ingrowth, mechanical dysfunction and calcifica-
tion, and leaflet tears for bioprostheses. This group excludes
patients with active prosthetic valve endocarditis and throm-
bosed mechanical valves.
3. Periprosthetic leak: Periprosthetic leak and a normally func-
tioning prosthesis. Patients with active endocarditis were
excluded.
4. Valve thrombosis: Thrombosis of the mechanical valve to
the extent that the thrombosis interfered with valve opening
characteristics. This group does not include patients who
had embolic phenomena only.
5. Prosthetic valve endocarditis: Patients with organisms or
inflammation documented on the valve specimen, or
patients who underwent operation while receiving pro-
longed antibiotic treatment for clinical endocarditis. Patients
with a history of endocarditis who underwent surgery for
valve dysfunction that was remote from prolonged antibiot-
ic treatment and whose valves showed neither organisms nor
active inflammation were considered to have “healed endo-
carditis” and were placed in other groups.
Operative mortality was defined as death within 30 days of
surgery or during the same hospital admission. The following vari-
ables were examined for their relationship with operative mortality:
1. Age in years
2. Sex
3. Year of reoperation
4. Indication for reoperation: Native/failed valve repair, pros-
thetic valve dysfunction, periprosthetic leak, endocarditis or
thrombosed valve
5. Procedure at repeat operation: Aortic valve replacement,
mitral valve replacement, combined aortic/mitral valve
replacement, tricuspid valve replacement (isolated or part of
multiple replacement), valve repair only, or isolated
periprosthetic leak repair
6. bypass grafting (CABG) (at initial operation or reoperation)
versus no CABG 
7. Reoperation for replacement of prosthetic valve:
Replacement of a mechanical valve versus replacement of a
tissue valve
Statistical Methods
The association between each variable and operative mortality was
investigated by means of the χ2 test or the Fisher exact test depend-
ing on the table; classes were combined where necessary. Possible
trends in ordinal variables were examined by the χ2 test for trend.
Multivariable analysis of the entire group was based on logistic
regression modeling with operative mortality as the outcome vari-
able. Because of the low incidence of operative mortality and the
number of events (58), the number of variables in the models con-
sidered was limited to approximately 6, as recommended by Peduzzi
and coworkers.3 Variables were selected on the basis of their clinical
importance and their significance level (P < .2) in the univariable
analysis.2 The contributions of variables and their interactions were
assessed for significance by use of differences of log likelihoods. A
similar multivariable analysis was performed on the subgroup of
patients who underwent replacement of prosthetic valves. There
were 45 events in 336 patients. Analyses were performed with the
use of SPSS for Windows version 8.0 (SPSS, Inc, Chicago, Ill).
Results
Over a 30-year period, from January 1969 until December
1998, 671 patients (242 men and 429 women) with a mean
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TABLE 1. Mortality associated with decade of reoperation
Decade Age (y; mean and range)* Mean age at deaths* (y) Mortality† Percentage†
1969-1978 46 (17-73) 50 21/130 16.2
1979-1988 53 (16-77) 56 22/226 9.7
1989-1998 60 (18-83) 64 15/315 4.8
*Age and time are positively correlated but there is no statistically significant interaction between them.
†χ2 for linear trend P < .0005 with decreased mortality in recent decades. 
TABLE 2. Indication for reoperation
Indication Mortality Percentage
Failed repair/new native valve 9/299 3.0
disease
Prosthetic valve dysfunction or 34/321 10.6*
periprosthetic leak
Endocarditis or thrombosed valve 15/51 29.4*†
*P < .0005 compared with “Failed repair/New native valve disease.”
†P < .0005 compared with “Prosthetic valve dysfunction or periprosthetic
leak.” 
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age of 54.7 years (range 16-83 years) underwent first reop-
eration on a heart valve with an overall operative mortality
of 8.6%. Mortality was 35 of 429 (8.2%) for women and 23
of 242 (9.5%) for men (P > .2). The age of those patients
who had an operative death was 55.9 years (standard devia-
tion [SD] 10.9) compared with 54.6 years (SD 13.1) for
those who survived surgery (P > .2). 
The approximate halving in mortality (χ2 for linear trend
P < .0005), despite the increasing average age of the
patients for successive decades during the study period, is
shown in Table 1. Analysis of the year of operation as a con-
tinuous variable after adjusting for other factors likewise
demonstrated that operative deaths occurred with greater
incidence earlier in the period (P < .0005) (see Table 5).
Reoperation on a previously repaired valve or for new
native valve disease was associated with a mortality of 3.0%
compared with 13.2% after previous valve replacement (P <
.0005). Some of the initial repairs were closed mitral valvot-
omies, but mortality after reoperation on these patients was
similar (2.3%) to that after open valve repair. 
Among patients with previous valve replacements, mor-
tality was higher when the indication was endocarditis or
thrombosed valve (29.4%) compared with prosthetic valve
dysfunction or periprosthetic leak (10.6%), as indicated in
Table 2 (P < .0005). Valve thrombosis occurred only in
mechanical valves. Mortality was 2 of 4 in the aortic posi-
tion, 4 of 17 in the mitral position, and 2 of 2 in the tricus-
pid position. Mortality after surgery for periprosthetic leak
was similar for repair of leak (4/31) and valve replacement
for leak (3/33). There was little difference between repair
and replacement at either the aortic or mitral positions (1/3
vs 1/11, aortic position; 3/25 vs 1/16, mitral position). 
The mortality according to the procedures performed at
reoperation is shown in Table 3. Mortality of aortic valve
replacement at the first reoperation was 6.4% and remained
low in the most recent decade (5.0%, 5/101). Mortality was
33.3% (2/6) if a concomitant ascending aortic graft was
required (P = .059). Mortality of mitral valve replacement at
the first reoperation was 7.4% and fell slightly in the most
recent decade (4.7%, 6/127). Concomitant repairs to other
valves were associated with a mortality of 11.4% (4/35)
compared with 6.8% (16/234) for isolated mitral valve
replacement (P > .2). Mortality was 11.5% (14/122) after
previous valve replacement compared with 4.1% (6/147)
after repair (P = .019). Mortality of combined aortic and
mitral valve replacement at first reoperation was 11.5%
(12/104), and this fell in the most recent decade (3.5%,
2/57). Concomitant tricuspid valve repair was associated
with a mortality of 13.3% (2/15) compared with 11.2%
(10/89) when it was not required. Mortality was 19.0%
(11/58) after previous valve replacement compared with
2.2% (1/46) after repair (P = .011). Mortality was not relat-
ed to the initial site of valve replacement: 16.7% (3/18) after
initial combined aortic and mitral valve replacements, 25%
(5/20) after aortic valve replacement, and 15% (3/20) after
mitral valve replacement. Few patients required tricuspid
valve replacement, but the mortality was high (25.6%,
11/43). There was no significant difference between isolat-
ed tricuspid valve replacement and tricuspid valve replace-
ment as part of a multiple valve replacement. Although the
numbers were small, tricuspid valve replacement remains an
operation with a high mortality of 40% (2/5) in the most
recent decade. Valve repair was associated with a mortality
of 2.0%, the only death occurring in an isolated tricuspid
valve repair.
Concomitant CABG at either the initial or repeat valve
procedure was associated with a mortality of 15.4% (6/39)
compared with 8.2% (52/632) when CABG was not
required (P = .14). 
The causes of operative mortality are shown in Table 4.
Nine patients died on the operating table. The cause of death
was myocardial failure in 5, left ventricular rupture in 2, and
acute myocardial infarction and acute endocarditis in 1 each.
A further 8 patients died later on the day of the operation.
Heart failure was responsible in 6 patients and uncontrol-
lable hemorrhage in 2 patients, due to left ventricular rupture
in 1 of them. One other patient died of left ventricular rup-
ture on the first postoperative day. The 4 patients who had
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TABLE 3. Mortality according to principal valve procedure
at reoperation
Principal procedure Mortality Percentage
Aortic valve replacement 12/187 6.4
Mitral valve replacement 20/269 7.4
Aortic/mitral valve replacement 12/104 11.5
Tricuspid valve replacement 11/43 25.6
Isolated periprosthetic leak repair 2/22 9.1
Valve repair only 1/46 2.2
TABLE 4. Cause of operative mortality
Cause of death No. of patients Percentage
Myocardial failure 30 51.7
Hemorrhage 9 15.5
Endocarditis 6 10.3
Bronchopneumonia 4 6.9
Myocardial infarction 3 5.2
Multiple organ failure 2 3.5
Renal failure 2 3.5
Cerebrovascular accident 1 1.7
Acute abdomen 1 1.7
Total 58
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left ventricular rupture had mitral valve replacements at
reoperation. Of the 58 patients who died in the hospital, 26
(49.1%) patients had a postmortem examination performed.
Multivariable Analysis
The final logistic regression model shown in Table 5 is based
on the explanatory variables age, time of reoperation (in years
from the start of the study period, ie, 1969), both considered
as continuous variables, and the categorical variables CABG
and one representing the various indication categories. The
interaction effects of these variables were examined and
found to be nonsignificant except for the age × indication and
CABG × indication effects. However, both interaction mod-
els showed signs of overfitting and were rejected. Increased
risk of mortality was associated with older age, decreasing
time (or earlier year of reoperation), concomitant CABG at
either the initial or repeat valve operation, and the indication
categories compared with the reference category (failed
repair/new native valve disease). In addition, time of reopera-
tion (expressed in decades) has an odds ratio of 0.39 (95%
confidence intervals [CI] 0.25 to 0.60). 
Replacement of Prosthetic Valves 
We reviewed the 336 patients who required replacement of
a prosthetic valve at reoperation. Patients who required
replacement of a tissue valve at reoperation had a mortality
of 8.6% (21/244) compared with 26.1% (24/92) if replace-
ment of a mechanical valve was required (P < .0005). The
increased mortality after replacement of a mechanical valve
occurred with aortic valve replacements (P = .002), mitral
valve replacements (P = .061), combined aortic and mitral
valve replacements (P = .13), and tricuspid valve replace-
ments (P > .2), as shown in Figure 1.
Logistic regression modeling was carried out on the
explanatory variables age, time of reoperation (in years
from the start of the study period, ie, 1969), type of valve
explanted (mechanical vs tissue), and indication (endocardi-
tis or thrombosed valve compared with prosthetic dysfunc-
tion or periprosthetic leak). No interaction effects were
found to be significant. The final model is given in Table 6.
Increased risk of mortality was associated with earlier year
of reoperation, replacement of a mechanical valve compared
with a tissue valve, and the indication category endocarditis
or thrombosed valve compared with prosthetic dysfunction
or periprosthetic leak. 
Discussion
Mortality at heart valve reoperations is higher than at pri-
mary valve procedures.1 However, patients undergoing
heart valve reoperations are a heterogeneous group. Patients
differ in terms of their initial valve operation, as well as in
factors relating to the reoperation. The aim of this study was
to identify the risk factors for operative mortality among
patients undergoing first heart valve reoperation. 
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TABLE 5. Logistic regression analysis for 671 patients undergoing heart valve reoperation
Explanatory variable Estimated regression coefficient OR CL P value
Age (y) 0.04 1.04 1.01-1.07 .009
Time (y) –0.09 0.91 0.87-0.95 <.0005
CABG 1.23 3.41 1.24-9.37 .017
Indication*
Prosthetic dysfunction or periprosthetic leak 1.17 3.22 1.50-6.94 .003
Valve thrombosis or prosthetic valve endocarditis 2.55 12.84 5.04-32.71 <.0005
Constant –4.13
OR, Odds ratio; CL, confidence limits; CABG, coronary artery bypass grafting.
*The reference category for indication is “Failed repair/new native valve disease.”
TABLE 6. Logistic regression analysis for 336 patients undergoing replacement of a prosthetic valve
Explanatory variable Estimated regression coefficient OR CL P value
Age (y) 0.02 1.02 0.99-1.05 .143
Time (y) –0.07 0.93 0.89-0.98 .004
Mechanical valve 0.81 2.25 1.09-4.63 .028
Valve thrombosis or prosthetic valve endocarditis* 1.09 2.97 1.32-6.66 .008
Constant –2.73
OR, Odds ratio; CL, confidence limits.
*The indication category “Valve thrombosis or prosthetic valve endocarditis” is compared with “Prosthetic valve dysfunction or periprosthetic leak.”
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Overall mortality for those undergoing first heart valve
reoperation was only 8.6%, which is similar to the results
published by Lytle2 (10.9%), Cohn4 (10.1%), Akins5
(7.3%), Pansini6 (9.6%), Tyers7 (11.0%), and their associ-
ates. 
The risk at reoperation for those patients who had an ini-
tial reparative procedure or who were undergoing surgery
for new native valve disease was extremely low (3.0%).
Such patients were probably not as severely compromised
as those requiring surgery on a prosthetic valve. The extent
of surgical dissection within the heart would have been less
in those who did not require explantation of a previously
inserted prosthetic valve. The majority of these patients had
a previous mitral valve repair. Although some of these oper-
ations were closed mitral valvotomies, the operative mortal-
ity was similar after an open or a closed procedure. This
encourages the use of valve repair where possible because
the risk at reoperation is not increased. Gillinov,8
Niederhauser,9 and their associates found an operative mor-
tality of 8.6% and 8.8%, respectively, after reoperation for
failed mitral valve repair, which contrasts with our findings. 
Mortality was higher for those patients requiring reoper-
ation on a prosthetic valve. The risk at reoperation for
periprosthetic leak was not influenced by whether the reop-
eration was a repair of the leak or a valve replacement.
Operative mortality was similar for repair of leaks and
replacement in both the aortic and mitral positions.
Reoperation for thrombosed valves and endocarditis were
both associated with a high operative mortality. 
Operative mortality was higher at all valve positions for
those patients who required replacement of a mechanical
valve compared with a tissue valve. This agrees with the
findings of Tyers,7 Magilligan,10 Bortolotti,11 and their col-
leagues but is in contrast to the results published by others
who found no difference.2,12 The multivariable model
retained removal of a mechanical valve, year of reoperation,
and the indication for reoperation as significant explanatory
variables suggesting that, for all indications and years,
patients with mechanical valves in situ at reoperation have a
higher operative mortality. A possible explanation may be
that valve function deteriorates abruptly (eg, thrombosis) in
some patients, with consequent decompensation before a
relatively urgent operation. An example of this within our
series was the group of patients who required reoperation
for thrombosed mechanical valves. Cohn and coworkers13
found that New York Health Association class IV and emer-
gency operation were significant factors in raising the mor-
tality of reoperation. Otherwise, they found no difference in
the mortality of reoperation and primary heart valve
replacement. We did not review the preoperative New York
Heart Association class or urgency of the operation because
of an inability to ascertain this information from the patient
records without possible bias in a retrospective study.
However, despite greater numbers of mechanical valves
being inserted in this unit, fewer patients required replace-
ment of mechanical valves than tissue valves, and thus these
figures cannot be used to influence the choice of prosthesis
to be inserted at the initial operation. 
Mortality in the group of patients who required a tricus-
pid valve replacement at reoperation was high. This risk at
reoperation, however, compares favorably with other
series.14,15 Such patients represent a sick population with
severely compromised right ventricular function. 
Coronary artery disease had a detrimental effect on the
outcome after repeat valve surgery, which was significant in
the multivariable model. Others have found the presence of
CABG to be of borderline significance.2,4 Again, this is an
indication of compromised status with multiple pathologic
conditions. 
Sex had no effect on the outcome, an observation that
agrees with the conclusions of Cohn and associates.4 This
contrasts with the conflicting findings of Lytle and col-
leagues,2 who found that women undergoing reoperation on
the aortic valve had an increased risk, and Akins and col-
leagues,5 who found that men undergoing valve reoperation
at any site had an increased operative mortality. 
Age was not a risk factor in the univariable analysis, but it
was significant in the multivariable model. Again, reported
series differ, with some finding age to be associated with
increased risk2,5 whereas others have found no such associa-
tion.4
Mortality was lowest in the most recent decade (4.8%).
The reason for the falling mortality is most likely due to
improvements in intraoperative and perioperative care. In
particular, the improvements in myocardial protection with
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Figure 1. Operative mortality associated with replacement of
mechanical and tissue prosthetic valves according to site of oper-
ation. AVR, Aortic valve replacement; MVR, mitral valve replace-
ment; AVR/MVR, combined aortic and mitral valve replacements;
TVR, tricuspid valve replacement.
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multidose cardioplegia would have had a major role in
reducing the mortality in the mid-1970s. Improved monitor-
ing facilities in intensive care units would also have con-
tributed to a reduction in operative mortality despite an
older population. 
The majority of deaths were due to cardiac causes, espe-
cially myocardial failure, which indicates the severely com-
promised state of these patients. Nine patients died of
uncontrollable bleeding. In 4 of these patients the reason
was left ventricular rupture after mitral valve replacement.
This problem persisted despite awareness of the risk, with 2
deaths in each of the periods 1979-1988 and 1989-1998. 
In conclusion, we have shown in this large series that
repeat heart valve surgery can be performed with an accept-
able operative mortality that compares favorably with
results in other published series. We have confirmed that the
risk has fallen with the passage of time. However, several
categories of patients have an increased risk of death at
reoperation. These include older patients and those who had
CABG at the time of their previous valve operation or who
require concurrent CABG at valve reoperation. In addition,
the indication for reoperation, especially thrombosed valves
or prosthetic valve endocarditis, carries an increased risk,
and greater caution should be exercised in patients who
require replacement of a mechanical valve than a tissue
valve.
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